, /PRNewswire/ -- (Nasdaq: ) ("IceCure", "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the Company's management, will participate in the Northland Capital Markets Virtual Growth Conference on . "We have achieved our primary objectives for the first half of 2024, including the completion of the ICE3 trial and data results submission to the FDA, and being able to share our progress with investors at the Northland conference is timely as we firmly believe in the value that we are creating," commented , Chief Executive Officer. "Furthermore, we believe recent action taken by several members of the Board and senior executives to purchase several tens of thousands of shares in the open market demonstrate their continuing confidence in the Company.
Our entire team is optimistic about IceCure's potential to offer minimally-invasive options that are safe and just as effective as surgery for a growing number of indications worldwide, including early-stage breast cancer." The Company's Chief Executive Officer, , and Chief Financial Officer, , will provide an overview of IceCure Medical and review the latest developments and catalysts, including the completion of the ICE3 trial and pending De Novo Classification Request with the U.S.
Food and Drug Administration ("FDA") for marketing clearance of the ProSense® Cryoablation .
